Literature DB >> 23255942

Predictive markers for the response to 5-fluorouracil therapy in cancer cells: Constant-field gel electrophoresis as a tool for prediction of response to 5-fluorouracil-based chemotherapy.

E M Saleh1, R A El-Awady, N Anis.   

Abstract

The prediction of response or severe toxicity and therapy individualisation are extremely important in cancer chemotherapy. There are few tools to predict chemoresponse or toxicity in cancer patients. We investigated the correlation between the induction and repair of DNA double-strand breaks (DSBs) using constant-field gel electrophoresis (CFGE) and evaluating cell cycle progression and the sensitivity of four cancer cell lines to 5-fluorouracil (5FU). Using a sulphorhodamine-B assay, colon carcinoma cells (HCT116) were found to be the most sensitive to 5FU, followed by liver carcinoma cells (HepG2) and breast carcinoma cells (MCF-7). Cervical carcinoma cells (HeLa) were the most resistant. As measured by CFGE, DSB induction, but not residual DSBs, exhibited a significant correlation with the sensitivity of the cell lines to 5FU. Flow cytometric cell cycle analysis revealed that 14% of HCT116 or HepG2 cells and 2% of MCF-7 cells shifted to sub-G1 phase after a 96-h incubation with 5FU. Another 5FU-induced cell cycle change in HCT116, HepG2 and MCF-7 cells was the mild arrest of cells in G1 and/or G2/M phases of the cell cycle. In addition, 5FU treatment resulted in the accumulation of HeLa cells in the S and G2/M phases. Determination of Fas ligand (Fas-L) and caspase 9 as representative markers for the extrinsic and intrinsic pathways of apoptosis, respectively, revealed that 5FU-induced apoptosis in HCT116 and HepG2 results from the expression of Fas-L (extrinsic pathway). Therefore, the induction of DNA DSBs by 5FU, detected using CFGE, and the induction of apoptosis are candidate predictive markers that may distinguish cancer cells which are likely to benefit from 5FU treatment and the measurement of DSBs using CFGE may aid the prediction of clinical outcome.

Entities:  

Year:  2012        PMID: 23255942      PMCID: PMC3525493          DOI: 10.3892/ol.2012.965

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  35 in total

1.  Screening for dihydropyrimidine dehydrogenase deficiency.

Authors:  Jean L Grem
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

2.  p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines.

Authors:  I Petak; D M Tillman; J A Houghton
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

3.  Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer.

Authors:  Frank A Sinicrope; Zhineng Jayson Yang
Journal:  Future Oncol       Date:  2011-03       Impact factor: 3.404

Review 4.  Metabolism and mechanism of action of 5-fluorouracil.

Authors:  W B Parker; Y C Cheng
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

Review 5.  DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets.

Authors:  Long Shan Li; Julio C Morales; Martina Veigl; David Sedwick; Sheldon Greer; Mark Meyers; Mark Wagner; Richard Fishel; David A Boothman
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

6.  Apoptosis is the most efficient death-pathway in tumor cells after topoisomerase II inhibition.

Authors:  Raafat A El-Awady; Mahmoud M Ali; Ekram M Saleh; Fayek M Ghaleb
Journal:  Saudi Med J       Date:  2008-04       Impact factor: 1.484

Review 7.  A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?

Authors:  Miriam Koopman; Sabine Venderbosch; Iris D Nagtegaal; Johan H van Krieken; Cornelis J Punt
Journal:  Eur J Cancer       Date:  2009-05-25       Impact factor: 9.162

8.  Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.

Authors:  Christian N Arnold; Ajay Goel; C Richard Boland
Journal:  Int J Cancer       Date:  2003-08-10       Impact factor: 7.396

9.  The interaction of thymidylate synthase expression with p53-regulated signaling pathways in tumor cells.

Authors:  Daniel B Longley; Tariq Latif; John Boyer; Wendy L Allen; Pamela J Maxwell; Patrick G Johnston
Journal:  Semin Oncol       Date:  2003-06       Impact factor: 4.929

Review 10.  DNA repair pathways as targets for cancer therapy.

Authors:  Thomas Helleday; Eva Petermann; Cecilia Lundin; Ben Hodgson; Ricky A Sharma
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

View more
  9 in total

1.  Adriamycin resistance-associated prohibitin gene inhibits proliferation of human osteosarcoma MG63 cells by interacting with oncogenes and tumor suppressor genes.

Authors:  Min-Dong Du; Kai-Yi He; Gang Qin; Jin Chen; Jin-Yi Li
Journal:  Oncol Lett       Date:  2016-07-14       Impact factor: 2.967

2.  shRNA-mediated GSTP1 gene silencing enhances androgen-independent cell line DU145 chemosensitivity.

Authors:  Peng Jin; Jinliang Xie; Xiangrong Zhu; Cheng Zhou; Xiang Ding; Luoyan Yang
Journal:  Int Urol Nephrol       Date:  2013-12-11       Impact factor: 2.370

3.  Inhibition of exosome release by ketotifen enhances sensitivity of cancer cells to doxorubicin.

Authors:  Farman Matloob Khan; Ekram Saleh; Hussain Alawadhi; Rania Harati; Wolfram-Hubertus Zimmermann; Raafat El-Awady
Journal:  Cancer Biol Ther       Date:  2017-12-15       Impact factor: 4.742

4.  Xiao-Ai-Ping, a TCM Injection, Enhances the Antigrowth Effects of Cisplatin on Lewis Lung Cancer Cells through Promoting the Infiltration and Function of CD8(+) T Lymphocytes.

Authors:  Wanshuai Li; Yang Yang; Zijun Ouyang; Qi Zhang; Lu Wang; Feifei Tao; Yongqian Shu; Yanhong Gu; Qiang Xu; Yang Sun
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-17       Impact factor: 2.629

Review 5.  Efficacy and toxicity of different concurrent chemoradiotherapy regimens in the treatment of advanced cervical cancer: A network meta-analysis.

Authors:  Zhan-Zhao Fu; Kun Li; Yong Peng; Yue Zheng; Li-Yan Cao; Yun-Jie Zhang; Yong-Mei Sun
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

6.  Combination treatment with 6-mercaptopurine and allopurinol in HepG2 and HEK293 cells - Effects on gene expression levels and thiopurine metabolism.

Authors:  Sofie Haglund; Svante Vikingsson; Sven Almer; Jan Söderman
Journal:  PLoS One       Date:  2017-03-09       Impact factor: 3.240

7.  Antioxidant and anticancer activities of Trigonella foenum-graecum, Cassia acutifolia and Rhazya stricta.

Authors:  Bayan Al-Dabbagh; Ismail A Elhaty; Ala'a Al Hrout; Reem Al Sakkaf; Raafat El-Awady; S Salman Ashraf; Amr Amin
Journal:  BMC Complement Altern Med       Date:  2018-08-22       Impact factor: 3.659

8.  CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance.

Authors:  Hiroyuki Minemura; Kiyoshi Takagi; Ai Sato; Hikaru Takahashi; Yasuhiro Miki; Yukiko Shibahara; Mika Watanabe; Takanori Ishida; Hironobu Sasano; Takashi Suzuki
Journal:  Cancer Sci       Date:  2016-12-01       Impact factor: 6.716

9.  Synergistic Interactions of 5-Fluorouracil with Inhibitors of Protein Kinase CK2 Correlate with p38 MAPK Activation and FAK Inhibition in the Triple-Negative Breast Cancer Cell Line.

Authors:  Patrycja Wińska; Olena Karatsai; Monika Staniszewska; Mirosława Koronkiewicz; Konrad Chojnacki; Maria Jolanta Rędowicz
Journal:  Int J Mol Sci       Date:  2020-08-28       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.